US Stem Company Executives
| USRM Stock | USD 0.0001 0.00 0.00% |
US Stem employs about 15 people. The company is managed by 7 executives with a total tenure of roughly 35 years, averaging almost 5.0 years of service per executive, having 2.14 employees per reported executive. Analysis of US Stem's management performance can provide insight into the firm performance.
| Sergio Pinski Insider Medical Board |
| Colleen Robb Insider Compliance Officer |
USRM |
US Stem Management Team Effectiveness
The company has return on total asset (ROA) of (8.4476) % which means that it has lost $8.4476 on every $100 spent on assets. This is way below average. US Stem's management efficiency ratios could be used to measure how well US Stem manages its routine affairs as well as how well it operates its assets and liabilities.US Stem Cell secures a total of 634.4 Million outstanding shares. US Stem Cell owns 10.68 % of its outstanding shares held by insiders and 0.0 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as US Stem in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of US Stem, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
US Stem Workforce Comparison
US Stem Cell is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 745. US Stem holds roughly 15.0 in number of employees claiming about 2.01% of equities under Health Care industry.
US Stem Cell Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. US Stem Cell Price Series Summation is a cross summation of US Stem price series and its benchmark/peer.
US Stem Notable Stakeholders
An US Stem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as US Stem often face trade-offs trying to please all of them. US Stem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting US Stem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sergio Pinski | Medical Board | Profile | |
| Colleen Robb | Compliance Officer | Profile | |
| Evelyn Flores | Co Controller | Profile | |
| Michael Tomas | President, CEO | Profile | |
| Phil Posa | Sr Sales | Profile | |
| James Greene | Clinical Consultant | Profile | |
| Fabianne Gershon | Consultant | Profile |
About US Stem Management Performance
The success or failure of an entity such as US Stem Cell often depends on how effective the management is. US Stem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of USRM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the USRM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
US Stem Workforce Analysis
Traditionally, organizations such as US Stem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare US Stem within its industry.US Stem Manpower Efficiency
Return on US Stem Manpower
| Revenue Per Employee | 204.8K | |
| Revenue Per Executive | 438.9K | |
| Net Loss Per Employee | 255.7K | |
| Net Loss Per Executive | 547.9K |
Other Information on Investing in USRM Pink Sheet
US Stem financial ratios help investors to determine whether USRM Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in USRM with respect to the benefits of owning US Stem security.